Requirement For Producer Cell Line For GMP Viral Vector Packaging
NHS Blood and Transplant · Awarded
- Buyer
- NHS Blood and Transplant
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Manufacturing
- Reference
- FaT-ocds-h6vhtk-032e03
- Published
- 2022-04-14
- Deadline
- 2026-05-07
Tender summary
NHSBT’s Clinical Biotechnology Centre for the purpose of specifying the user requirement for HEK293-derived production cell line for the GMP-production of viral vectors and other recombinant proteins. The CBC has an MHRA licence for the manufacture of investigational medicinal gene therapy and recombinant protein products for use in clinical trials. In order to manufacture GMP-grade viral vectors and recombinant proteins for clinical trials, a GMP-qualified producer cell line is required.
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access